GHIT Fund Invests $8.5 Million in Malaria and NTD Drug Development with GSK, Eisai Partners

Key Takeaways

• GHIT Fund commits $8.5 million (JPY 1.37 billion) to five malaria and NTD drug development projects
• $4.4 million allocated specifically for preclinical antimalarial drug development targeting 280+ million affected patients
• Partnership includes major pharmaceutical companies GSK, Tanabe Pharma, Eisai, MMV, and DNDi for global health initiatives

---

TOKYO - The Global Health Innovative Technology (GHIT) Fund announced a substantial $8.5 million investment in drug development projects targeting malaria and neglected tropical diseases (NTDs), partnering with leading pharmaceutical companies including GSK, Eisai, and Tanabe Pharma.

The investment, totaling approximately JPY 1.37 billion, will fund five distinct research and development projects aimed at addressing critical global health challenges. The largest portion, $4.4 million (JPY 700 million), has been earmarked for preclinical development of a new antimalarial drug.

Addressing Critical Global Health Needs

Malaria remains one of the world’s most devastating infectious diseases, affecting more than 280 million people annually and claiming approximately 610,000 lives. The disease disproportionately impacts vulnerable populations in sub-Saharan Africa, Southeast Asia, and Latin America, where access to effective treatments remains limited.

The GHIT Fund’s investment strategy focuses on leveraging partnerships between Japanese pharmaceutical companies and international organizations to accelerate drug discovery for diseases that primarily affect low- and middle-income countries.

Strategic Pharmaceutical Partnerships

The collaboration brings together diverse expertise from multiple organizations:

• Medicines for Malaria Venture (MMV): Leading product development partnership for antimalarial medicines
• GSK: Global pharmaceutical giant with extensive tropical disease research capabilities
• Tanabe Pharma and Eisai: Japanese pharmaceutical companies contributing local innovation
• Drugs for Neglected Diseases initiative (DNDi): Non-profit organization focused on developing treatments for neglected diseases

This multi-stakeholder approach combines Japanese innovation with global health expertise, potentially accelerating the timeline from laboratory research to patient access.

Market Impact and Future Outlook

The investment represents a significant commitment to addressing diseases that affect over one billion people worldwide but receive limited commercial research funding due to market constraints. By supporting preclinical development, the GHIT Fund aims to de-risk early-stage research and encourage continued investment in later-stage clinical trials.

The funding announcement comes as global health organizations emphasize the need for new therapeutic approaches to combat drug-resistant malaria strains and address treatment gaps in NTD management.

---

Frequently Asked Questions

What diseases will benefit from this GHIT Fund investment?

The $8.5 million investment targets malaria, which affects over 280 million people annually, and various neglected tropical diseases (NTDs) that impact over one billion people in low- and middle-income countries.

When will these new treatments be available to patients?

The funding supports preclinical development, which typically takes 3-5 years before advancing to human clinical trials. Patient access would likely require an additional 5-10 years depending on clinical trial success and regulatory approval.

How does this investment compare to other global health funding initiatives?

The $8.5 million represents a significant commitment to early-stage drug development for diseases that receive limited commercial investment. GHIT Fund’s model of combining Japanese pharmaceutical expertise with international partners offers a unique approach to global health R&D funding.